MIM
LBRX

Monashee Investment Management’s LB Pharmaceuticals LBRX Stock Holding History

Monashee Investment Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$632K – 80
2025
Q3 		$632K Buy
+40,000
New +$635K 0.32% 57

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

Monashee Investment Management's LBRX Position: Q4 2025 in Review

Monashee Investment Management sold out of LB Pharmaceuticals (LBRX) in Q4 2025, closing a stake of 40,000 shares — an estimated $632K sold.

Monashee Investment Management first reported a position in LBRX in Q3 2025 and held it in 1 quarter. The position peaked at $632K in Q3 2025. 68 funds tracked by Wall St. Rank hold LBRX as of Q4 2025.

  • Monashee Investment Management reported no remaining LB Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Monashee Investment Management sold 40,000 LB Pharmaceuticals shares in Q4 2025, an estimated $632K.
  • Monashee Investment Management first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Monashee Investment Management's LB Pharmaceuticals position peaked at $632K in Q3 2025.
  • 68 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q4 2025.

Based on Monashee Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.